Coagulation Abnormalities in Malignancy
Keywords:
-Abstract
-
Downloads
References
Trousseau A. Phlegmasia alba dolens. In: Clinique medicale de l'Hotel-Dieu de Paris. Paris, JB Balliere et Fils. 1865:3:654-712.
Billroth T. Lectures on Surgical Pathology and Therapeutics: A Handbook for Students and Practitioners. Translated from the 8 edition. London, The New Sydenham Society, 1877-8.
Sprowl EE. Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Med Sci 1938;34:566-85.
Saphir O. The fate of carcinoma embol in the lung. Am J Pathol 1947:23:245-53.
O'Meara RAQ. Coagulative properties of cancers. Ir J Med Sci 1958,6:474.
Hiramoto R, Bemecky J, Jurandowski J, et al. Fibrin in human tumors. Cancer Res 1960;20:592-3.
Dvorak HF, Dvorak AM, Manseau EJ, et al. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs: Role of cellular immunity, myofibroblasts, microvascular damage, and infarotion in line 1 tumor regression. J Natl Canoer Inst 1979,62:1459-72.
Harris NL, Dvorak AM, Smith J, et al. Fibrin deposits in Hodgkin's disease. Am J pathol 1982;108:119-29.
Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
Dvorak HF, Harvey VS, McDonagh J. Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. Cancer Res 1984:44:33-48.
Brown LF, Van De Water L, Harvey VS, et al. Fibrinogen influx and accumulation of crosslinked fibrin in healing wounds and in tumor stroma. Am J Pathol 1988130.455-65.
Spar IL, Bale WF, Marrack D, et al. 131H-labelled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials. Cancer 1967;20:865-70.
Virchow R. Gesammelte Abhaldungen zur Wissensdiafflichem Medicine. Frankfurt; Meidinger Sohn, 1856; p. 447.
Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am 1990;89:25-8.
Edwards RL, Klaus M, Matthews E, et al. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med 1990;89:25-8.
Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001;102:V215-V224.
Rickles FR, Levine M, Dvorak HB. Abnormalities of hemostasis in malignancy. In: Hemostasis and Thrombosis, 4 ed. Colman RW, Hirsh J, Marder VJ, et al. (eds.) Philadelphia: Lippincott Williams & Wilkins, 2000:1131-52.
Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999;25:173-82.
Van de Water L, Tracy PB, Aronson D, Mann KG, Dvorak HF. Tumour cell generation of thrombin via functional prothrombinase assembly. Cancer Res 1985;45:5521-
Yoshida E, Verrusio EN, Mihara H, Oh D, Kwaan HC. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res 1994;54:3300-4.
Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancers.
Am J Pathol 1998;152:399-411.
Contrino J, Hair GA, Kreutzer DL, et al. In situ detection of the expression of tissue factor in vascular endothelial cells:correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-15.
Shoji M, Abe K, Nawroth PP, et al. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardiovasc Med 1997;7:52-9.
Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmictail of tissue factor. Proc Nat Acad Sci USA 1999:96:8663-8.
Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996:2:167-8.
Steingart RH. Coagulation disorders associated with neoplastic disease. Recent Results Cancer Res 1988;108:37-43.
Ratnoff OD. Hemostatic emergencies in malignancy. Semin Oncol 1989;16:561-71.
Selroos O. Thrombocytosis. Acta Med Scand 1973;193:431-6.
Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med. 1964;114:497-500.
Goldsmith GH Jr. Hemostatic disorders associated with neoplasia. In: Ratnoff OD, Forbes CD, (Eds.): Disorders of Hemostasis. 2nd ed. Philadelphia: Grune & Stratton, 1991:352-68.
Sun NC, McAffee WM, et al. Hemostatic abnormalities in malignancy, a prospective study of 108 patients. Am J Clin Pathol 1979,71:10-6.
Kies MS, Posch JJ, Giolma JP, et al. Hemostatic function in cancer patients. Cancer 1980;46:831-7.
Hagedorn AB, Bowre EFW, Elveback LR, et al. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc
;49:647-53.
Davis RB, Theologides A, Kennedy BJ. Comparative studies of blood coagulation and platelet aggregation in patients with cancer and nonmalignant disease. Ann Intern Med 1969;71:67-80.
Tranum BL, Haut A. Thrombocytosis: Platelet Kinetics in neoplasia. J Lab Clin Med 1974;84:615-9.
Cooper HA, Bowie EJW, Owen CA Jr. Evaluation of patients with increased fibrinolytic split products in their serum. Mayo Clin Proc 1974;49:654-7.
Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 198788596-602.
Bidet JM, Ferriere JP, Besse G, et al Evaluation of B-thromboglobulin levels in cancer patients: Effects of antitumor therapy. Thromb Res 1980;19:429-33.
Slichter SJ, Harker LA. Hemostasis in malignancy. Ann NY Acad Sci 1974;230:252-61.
Johannson S, Kutti J, Olsson LB. Rapid platelet consumption in a case of metastatic osteogenic sarcome of the breast. Acta Pathol Microbiol Scand 1978:505:86A (abstr).
Schernthaner G, Ludwig H, Silberbasuer K. Elevated plasma B-thromboglobulin Jevels in multiple myeloma and in polycythaemia vera. Acta Haematol (Basel) 1979:62.219-22.
Francis JL. Haemostasis and cancer. Med Lab Sci 1989:46:331-46.
Boneu B, Bugat R, Boneu A, et al. Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathy. Eur J Cancer Clin Oncol 1984;20:899-903.
Sloand EM, Kenney DM, Chao FC, et al. Platelet anti-thrombin defect in malignancy: Platelet protein alterations. Blood 1987;69:479-85.
Barbui T, Finazzi G, Falanga A. The impact of all-trans-retionic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998;91:3093-102.
Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990;17:147-59.
Nand S, Fisher SG, Salgia R, et al. Hemostatic abnormalities in untreated cancer: Incidence and correlation with thrombotic and hemorrhagic complication. J Clin Oncol 1987;5.1998-2003.
Rasche H, Dietrich M. Hemostatic abnormalities associated with malignant diseases. Eur J Cancer 1977;13:1053-64.
Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am 1996;10:457-84.
Falanga A, Ofosu FA, Cortelazzo S, et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993:85:745-50.
Falanga A, Barbui T, Rickles FR, et al. Guidelines for clotting studies in cancer patients. Thromb Hameost 1993,70:343-50.
Hettiarachchi RJ, Lok J, Prins MH, Buller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998;83:180-5.
Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous thromboembolism and cancer. Lancet 1998;351:1077-80.
Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998:338:1169-73.
Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 2000;342:1953-8.
Piccioli A, Lensing AWA, Prins MH. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. Thromb Haemost 2001; (Suppl) July: Abstr number 900.
Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg. Is there a 'high risk' group? Am J Surg 1970;120:527-30.
Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999:25:239-43.
Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 1975;i(7924):45-51.
Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913-30.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
